Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)
Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor (EGFR), and RET signaling. This placebo-controlled trial assessed whether vandetanib conferred an overall survival benefit in patients with advanced non-small-cell lung...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
April 2012
|
| In: |
Journal of clinical oncology
Year: 2012, Volume: 30, Issue: 10, Pages: 1114-1121 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2011.36.1709 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1200/JCO.2011.36.1709 Verlag, Volltext: http://ascopubs.org/doi/abs/10.1200/JCO.2011.36.1709 
|
| Author Notes: | Jin Soo Lee, Vera Hirsh, Keunchil Park, Shukui Qin, Cesar R. Blajman, Reury-Perng Perng, Yuh-Min Chen, Laura Emerson, Peter Langmuir, and Christian Manegold |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1571919821 | ||
| 003 | DE-627 | ||
| 005 | 20220814111724.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180411s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2011.36.1709 |2 doi | |
| 035 | |a (DE-627)1571919821 | ||
| 035 | |a (DE-576)501919821 | ||
| 035 | |a (DE-599)BSZ501919821 | ||
| 035 | |a (OCoLC)1341001929 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Lee, Jin Soo |e VerfasserIn |0 (DE-588)1155875036 |0 (DE-627)1018354107 |0 (DE-576)501919724 |4 aut | |
| 245 | 1 | 0 | |a Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor |b a randomized, double-blind phase III trial (ZEPHYR) |c Jin Soo Lee, Vera Hirsh, Keunchil Park, Shukui Qin, Cesar R. Blajman, Reury-Perng Perng, Yuh-Min Chen, Laura Emerson, Peter Langmuir, and Christian Manegold |
| 264 | 1 | |c April 2012 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.04.2018 | ||
| 520 | |a Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor (EGFR), and RET signaling. This placebo-controlled trial assessed whether vandetanib conferred an overall survival benefit in patients with advanced non-small-cell lung cancer (NSCLC) after prior treatment with an EGFR tyrosine kinase inhibitor and one or two chemotherapy regimens. | ||
| 700 | 1 | |a Manegold, Christian |d 1946-2022 |e VerfasserIn |0 (DE-588)108614913 |0 (DE-627)490287360 |0 (DE-576)289617200 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 30(2012), 10, Seite 1114-1121 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor a randomized, double-blind phase III trial (ZEPHYR) |
| 773 | 1 | 8 | |g volume:30 |g year:2012 |g number:10 |g pages:1114-1121 |g extent:8 |a Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor a randomized, double-blind phase III trial (ZEPHYR) |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.2011.36.1709 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://ascopubs.org/doi/abs/10.1200/JCO.2011.36.1709 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180411 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 108614913 |a Manegold, Christian |m 108614913:Manegold, Christian |d 60000 |d 61800 |e 60000PM108614913 |e 61800PM108614913 |k 0/60000/ |k 1/60000/61800/ |p 10 |y j | ||
| 999 | |a KXP-PPN1571919821 |e 3005809242 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"8 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1527-7755"],"zdb":["2005181-5"],"eki":["313116962"]},"origin":[{"dateIssuedDisp":"1983-","dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]"}],"recId":"313116962","language":["eng"],"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"American Society of Clinical Oncology"}],"disp":"Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor a randomized, double-blind phase III trial (ZEPHYR)Journal of clinical oncology","note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"text":"30(2012), 10, Seite 1114-1121","volume":"30","extent":"8","year":"2012","issue":"10","pages":"1114-1121"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"pubHistory":["1.1983 -"],"title":[{"subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology","title_sort":"Journal of clinical oncology"}]}],"name":{"displayForm":["Jin Soo Lee, Vera Hirsh, Keunchil Park, Shukui Qin, Cesar R. Blajman, Reury-Perng Perng, Yuh-Min Chen, Laura Emerson, Peter Langmuir, and Christian Manegold"]},"origin":[{"dateIssuedDisp":"April 2012","dateIssuedKey":"2012"}],"id":{"doi":["10.1200/JCO.2011.36.1709"],"eki":["1571919821"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 11.04.2018"],"recId":"1571919821","language":["eng"],"person":[{"given":"Jin Soo","family":"Lee","role":"aut","roleDisplay":"VerfasserIn","display":"Lee, Jin Soo"},{"display":"Manegold, Christian","roleDisplay":"VerfasserIn","role":"aut","family":"Manegold","given":"Christian"}],"title":[{"title":"Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor","subtitle":"a randomized, double-blind phase III trial (ZEPHYR)","title_sort":"Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor"}]} | ||
| SRT | |a LEEJINSOOMVANDETANIB2012 | ||